###begin article-title 0
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 59 60 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor-Shed PGE2 Impairs IL2Rgammac-Signaling to Inhibit CD4+ T Cell Survival: Regulation by Theaflavins
###end article-title 0
###begin p 1
Conceived and designed the experiments: TD. Performed the experiments: SC SB BS JC SM DMSH SB KD GS TD. Analyzed the data: SC SB GS TD. Wrote the paper: SC SB GS TD.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Many tumors are associated with decreased cellular immunity and elevated levels of prostaglandin E2 (PGE2), a known inhibitor of CD4+ T cell activation and inducer of type-2 cytokine bias. However, the role of this immunomodulator in the survival of T helper cells remained unclear. Since CD4+ T cells play critical roles in cell-mediated immunity, detail knowledge of the effect tumor-derived PGE2 might have on CD4+ T cell survival and the underlying mechanism may, therefore, help to overcome the overall immune deviation in cancer.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 22 27 <span type="species:ncbi:9606">human</span>
By culturing purified human peripheral CD4+ T cells or Jurkat cells with spent media of theaflavin- or celecoxib-pre-treated MCF-7 cells, we show that tumor-shed PGE2 severely impairs interleukin 2 receptor gammac (IL2Rgammac)-mediated survival signaling in CD4+ T cells. Indeed, tumor-shed PGE2 down-regulates IL2Rgammac expression, reduces phosphorylation as well as activation of Janus kinase 3 (Jak-3)/signal transducer and activator of transcription 5 (Stat-5) and decreases Bcl-2/Bax ratio thereby leading to activation of intrinsic apoptotic pathway. Constitutively active Stat-5A (Stat-5A1*6) over-expression efficiently elevates Bcl-2 levels in CD4+ T cells and protects them from tumor-induced death while dominant-negative Stat-5A over-expression fails to do so, indicating the importance of Stat-5A-signaling in CD4+ T cell survival. Further support towards the involvement of PGE2 comes from the results that (a) purified synthetic PGE2 induces CD4+ T cell apoptosis, and (b) when knocked out by small interfering RNA, cyclooxygenase-2 (Cox-2)-defective tumor cells fail to initiate death. Interestingly, the entire phenomena could be reverted back by theaflavins that restore cytokine-dependent IL2Rgammac/Jak-3/Stat-5A signaling in CD4+ T cells thereby protecting them from tumor-shed PGE2-induced apoptosis.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
These data strongly suggest that tumor-shed PGE2 is an important factor leading to CD4+ T cell apoptosis during cancer and raise the possibility that theaflavins may have the potential as an effective immunorestorer in cancer-bearer.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 105 108 105 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Phipps1">[1]</xref>
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Harris1">[3]</xref>
###xml 117 118 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Passwell1">[4]</xref>
###xml 270 273 270 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Cayeux1">[5]</xref>
###xml 409 412 409 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Yang1">[6]</xref>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Prostaglandins are lipid molecules regulating numerous processes including modulation of immune function [1]-[3]. PGE2 is produced by many different cell types, including malignant cells, and is known to contribute to cellular immune suppression in cancer patients [4], [5]. On the other hand, deletion of the respective prostaglandin receptors leads to reduced carcinogenesis and enhanced antitumor immunity [6].
###end p 9
###begin p 10
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 145 148 145 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Toes1">[7]</xref>
###xml 150 153 150 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Pardoll1">[8]</xref>
###xml 206 209 206 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Goedegebuure1">[9]</xref>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kennedy1">[10]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Huang1">[11]</xref>
###xml 369 370 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bennett1">[12]</xref>
###xml 572 573 572 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Marzo1">[13]</xref>
###xml 689 690 689 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Das1">[14]</xref>
###xml 846 850 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Finke1">[19]</xref>
###xml 902 903 902 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 983 987 983 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bhattacharyya2">[20]</xref>
###xml 989 993 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Mandal2">[21]</xref>
###xml 1044 1045 1044 1045 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 731 736 <span type="species:ncbi:9606">human</span>
###xml 737 745 <span type="species:ncbi:9606">patients</span>
###xml 956 964 <span type="species:ncbi:9606">patients</span>
Current paradigms suggest that CD4+ T cells play critical roles in the optimal induction and maintenance of clinically beneficial tumor immunity [7], [8]. These cells prime CTL-mediated antitumor responses [9] by preventing activation-induced cell death and functioning as antigen-presenting cells for CTLs to preferentially generate immune memory cells [10], [11]. CD4+ helper T cells also induce CD8+ cytotoxic T cell responses through dendritic cell activation by CD40/CD40L interactions [12] and determine the magnitude and persistence of such responses as well as CD8+ T cell infiltration of tumors [13]. Therefore, in order to establish itself, a growing tumor tries to overpower CD4+ T cells. It has been reported that both human patients and experimental animals with advanced cancer often exhibit a poorly functioning immune system [14]-[19]. There is evidence of increased apoptosis among CD4+ T cells in peripheral blood lymphocytes from cancer patients and animal models [20], [21]. Understanding the mechanisms of tumor-induced CD4+ T cell apoptosis as well as its amelioration by any biological response modifier is, therefore, of high importance from the point of view of amelioration of tumor-induced immuno-suppression.
###end p 10
###begin p 11
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 16 20 16 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Chemnitz1">[22]</xref>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 114 115 114 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Pockaj1">[23]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Minakuchi1">[24]</xref>
###xml 420 424 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Spierings1">[25]</xref>
###xml 449 450 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 471 475 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kolenko1">[26]</xref>
###xml 477 481 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bhattacharyya3">[27]</xref>
###xml 614 618 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Anastassiou1">[28]</xref>
###xml 620 624 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Alava1">[29]</xref>
###xml 639 640 635 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 730 734 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kolenko1">[26]</xref>
###xml 736 740 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bhattacharyya3">[27]</xref>
###xml 838 842 834 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kolenko1">[26]</xref>
###xml 844 848 840 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bhattacharyya3">[27]</xref>
###xml 944 945 940 941 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1142 1146 1138 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Yang2">[30]</xref>
###xml 1225 1226 1221 1222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1255 1259 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Wen1">[31]</xref>
###xml 1359 1363 1355 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Webb1">[32]</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 1177 1181 <span type="species:ncbi:10090">mice</span>
Chemnitz et al. [22] have reported impairment in CD4+ T cell activation in cancer patients by PGE2. Tumor-shed PGE2 has been found to mediate profound alteration in cytokine balance in the cancer microenvironment and thereby contributing to T cell suppression in cancer patients [23], [24]. In fact, IL2 and IL2Rgammac gene expression, that play crucial role in T cell proliferation, survival, and programmed cell death [25], are both targets of PGE2-induced suppression [26], [27], possibly through the inhibition of early events in T-cell signaling that include calcium influx and phosphatidylinositol breakdown [28], [29]. Moreover, PGE2 has been reported to down-regulate Jak-3 protein, which associates with IL2R, in T cells [26], [27]. This reduction in Jak-3 resulted in impaired phosphorylation and DNA binding activity of Stat-5 [26], [27]. Because Jak-3 is critical to IL2-dependent signaling and proliferation, its sensitivity to PGE2 may make it a prime target for suppressing IL2-dependent cell cycle progression in T cells. It is well accepted that Jak-mediated survival signals modulate Bcl-2 family of anti-apoptotic proteins [30]. Studies with Jak-3 deficient mice have showed down-regulation of Bcl-2 in CD8+ T cell population in thymus [31]. Other reports have demonstrated correlation between loss in Bcl-2 expression and death of T cells [32].
###end p 11
###begin p 12
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 137 138 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 145 146 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Saiagh1">[33]</xref>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Mastino1">[34]</xref>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Hilkens1">[35]</xref>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 545 548 545 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Toes1">[7]</xref>
###xml 550 553 550 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Pardoll1">[8]</xref>
###xml 597 598 597 598 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 670 671 670 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 733 734 733 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 771 772 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 827 828 827 828 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1262 1263 1250 1251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1295 1296 1283 1284 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1353 1354 1341 1342 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1507 1508 1495 1496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1545 1546 1533 1534 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
###xml 278 284 <span type="species:ncbi:10090">murine</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
###xml 661 666 <span type="species:ncbi:9606">human</span>
###xml 1202 1211 <span type="species:ncbi:4442">black tea</span>
###xml 1605 1613 <span type="species:ncbi:9606">patients</span>
Interestingly, although PGE2 has been implicated in the increase or the acceleration of the programmed cell death process of immature CD4+CD8+CD3+ thymocytes in culture [33], CD4+CD8+ thymocytes inside the thymus in mice [34], and favors Th2-like cytokine secretion profiles in murine and human CD4+ T cells [35], there is no detail report on its effect on CD4+ T cell survival, if any, and the underlying mechanism. Since these helper T cells play critical roles in the optimal induction and maintenance of clinically beneficial tumor immunity [7], [8], here we address the role tumor-derived PGE2 might have on CD4+ T cell survival. Using exclusively primary human CD4+ T cells we found a correlation between over-expression of PGE2 in tumor cells and tumor-induced CD4+ T cell apoptosis. Inhibitory effects of tumor-shed PGE2 were in fact dependent on impairment of IL2Rgammac signaling that lead to down regulation of IL2Rgammac, reduced phosphorylation of Jak-3 and Stat-5A and decreased expression of pro-survival protein Bcl-2. Additionally, we demonstrated release of cytochrome c from mitochondria to cytosol and activation of caspase cascade. It was interesting to note that theaflavins, the black tea polyphenols, protected IL2Rgammac signaling in CD4+ T cells from tumor-secreted PGE2 insult by inhibiting Cox-2 expression and subsequent PGE2 release from tumor cells. That these effects occurred in the absence of tumor cell-T cell contact negated the possibility of tumor contact-dependent CD4+ T cell apoptosis and highlighted PGE2 as an important mediator of impaired cellular immunity in patients with cancer.
###end p 12
###begin p 13
###xml 213 217 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Lahiry1">[36]</xref>
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Yang3">[38]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Dreger1">[39]</xref>
###xml 433 437 433 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Vermeer1">[40]</xref>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-uczaj1">[41]</xref>
###xml 717 721 717 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-uczaj1">[41]</xref>
###xml 108 117 <span type="species:ncbi:4442">black tea</span>
###xml 1020 1028 <span type="species:ncbi:9606">patients</span>
There are ample evidences demonstrating the biological impact of theaflavins. These bioactive flavonoids of black tea have been reported to induce cell growth inhibition and apoptosis in a variety of cancer cells [36]-[38] Theaflavins also exert a plethora of beneficial effects on the cardiovascular system [39] and play a role in decreased intestinal cholesterol absorption thereby being responsible for lowering blood-cholesterol [40]. Antioxidative properties of theaflavins are manifested by their ability to inhibit free radical generation, scavenge free radicals and down-regulate the activity of pro-oxidative enzymes [41]. They can also influence activation of transcription factors such as NFkappaB or AP-1 [41]. However, there was hardly any report suggesting the immunoprotective effect of theaflavins. Our findings signify that theaflavins can be a possible therapeutic agent with a strong immunomodulatory effect and therefore, in future can be used alone or in combination with tumoricidal drugs to treat patients with cancer.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cell-free tumor supernatant leads to CD4+ T cell depletion by inducing apoptosis
###end title 15
###begin p 16
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 111 118 111 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g001">Fig. 1A</xref>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 691 698 687 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g001">Fig. 1A</xref>
When purified CD4+ T cells were cultured in the presence of cell-free breast cancer cell (MCF-7) supernatants (Fig. 1A), a situation mimicking the tumor-bearing condition in which tumor-shed mediators influence the circulating CD4+ T cell repertoire, increase in the percent of dead CD4+ T cell (43.2%) in comparison to control (7.2%) was recorded. Interestingly, when these T cells were co-incubated with theaflavin-pretreated tumor culture supernatants, significant protection from tumor-induced death was observed in a theaflavin-dose-dependent manner, the optimum effect being at 25 microg/ml theaflavins (11.6% dead cells), beyond which no further significant change could be obtained (Fig. 1A). Subsequent studies were, therefore, carried out with this dose of theaflavins.
###end p 16
###begin title 17
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cell free tumor supernatant leads to CD4+ T cell depletion by inducing apoptosis.
###end title 17
###begin p 18
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 315 316 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 326 336 316 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 358 369 348 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</italic>
###xml 375 376 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 12 17 <span type="species:ncbi:9606">human</span>
A, Purified human peripheral CD4+ T cells were cultured in the presence of media alone or cell-free MCF-7-spent media (+/-theaflavins, doses from 6.25 microg/ml to 50 microg/ml). After 48 hours, viable cell numbers were scored by Trypan Blue exclusion method. B, Graphical representation of percent apoptosis of CD4+ T cells (left panel) and Jurkat T cells (right panel). CD4+ T cells labelled with Annexin V-PE and 7AAD were analyzed flow cytometrically. Annexin V/7AAD-positive cells were regarded as apoptotic cells. Values are mean+/-S.E.M. of five independent sets of experiments.
###end p 18
###begin p 19
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 325 326 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 561 562 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 626 627 626 627 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 637 644 637 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g001">Fig. 1B</xref>
###xml 305 310 <span type="species:ncbi:9606">human</span>
Depletion in CD4+ T cell populations by tumor supernatant prompted us to investigate the underlying cause. Next, to assess the mode of cell death, we used three-color flow cytometry (FITC-CD4, PE-Annexin-V and 7AAD). Results of Figure-1B depict that while cell-free MCF-7 supernatants caused apoptosis to human peripheral CD4+ T cells (38.4% in supernatant-treated cells and 5.5% in control) as well as Jurkat cells (42.5% in supernatant-treated cells and 8.2% in control), theaflavins furnished protection to them. Interestingly, theaflavins did not change CD4+ cell numbers significantly when applied directly to control CD4+ T cells (Fig. 1B).
###end p 19
###begin title 20
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor-shed PGE2 is responsible for CD4+ T cell apoptosis
###end title 20
###begin p 21
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 287 288 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 498 505 498 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2A</xref>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 596 597 596 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 631 638 631 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2B</xref>
###xml 807 808 807 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 850 857 850 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2A</xref>
###xml 925 926 925 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 965 966 965 966 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 994 1001 994 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2B</xref>
###xml 1058 1059 1058 1059 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1080 1081 1080 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1180 1181 1180 1181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1220 1228 1220 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Figure 2</xref>
###xml 1320 1321 1320 1321 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1323 1330 1323 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2A</xref>
###xml 1357 1358 1357 1358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1373 1380 1373 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2B</xref>
All the reactions so far defined occurred independent of direct contact of CD4+ cells with tumor cells or even proximity thereby pointing towards the possibility of the presence of tumor-shed soluble immunosuppressors in the supernatant. Our search revealed a significant increase in PGE2 in tumor supernatant in a time-dependent manner with a maximum at 72 hours of continuous culture while media from theaflavins-treated MCF-7 cells contained significantly lower levels of this immunosuppressor (Fig. 2A). Moreover, percent CD4+ cell apoptosis was positively correlated (r = 0.964) with the PGE2 level of individual supernatant (Fig. 2B), whereas theaflavin-pre-treated tumor supernatants failed to induce significant death. Importantly, insertion of Cox-2-siRNA in tumor cells blocked the increase in PGE2 in cell-free tumor supernatant overtime (Fig. 2A). This suggested inhibition in the generation and/or release of PGE2 that resulted in lesser killing of CD4+ cells than untreated ones (Fig. 2B). All these data confirmed the role of Cox-2-derived PGE2 in tumor-induced CD4+ T cell killing. These results prompted us to explore the possibility of theaflavins to inhibit PGE2 production in tumor cells. Results of Figure 2 indeed depicted that theaflavin-treated tumor cells secreted significantly low level of PGE2 (Fig. 2A) that displayed lesser CD4+ cell killing (Fig. 2B)
###end p 21
###begin title 22
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor-shed PGE2 is responsible for CD4+ T cell apoptosis.
###end title 22
###begin p 23
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 184 185 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 212 213 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 218 219 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 265 272 261 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2A</xref>
A, Tumor-secreted PGE2 over time in cell-free spent media of MCF-7 cells (control (o), Cox-2-siRNA-transfected (Delta) or theaflavin-treated (*) was determined by ELISA. B, Percent CD4+ T cell death (Annexin-V-PE+/7AAD+), induced by the spent media as described in Fig. 2A, was plotted over time. Values are mean+/-S.E.M. of three independent sets of experiments.
###end p 23
###begin title 24
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 47 48 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
PGE2 perturbs IL2Rgamma-signaling events in CD4+ T cells
###end title 24
###begin p 25
###xml 117 121 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Alves1">[42]</xref>
###xml 123 127 119 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Nakajima1">[43]</xref>
###xml 187 188 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 266 270 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Nakajima1">[43]</xref>
###xml 356 363 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3A</xref>
###xml 390 397 382 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3B</xref>
###xml 424 425 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 482 489 470 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3A</xref>
###xml 518 519 506 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 619 633 607 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3A and 3B</xref>
It is known that IL2 is essential for T cell homeostasis and activation for which it depends on IL2Rgammac signaling [42], [43]. Thus, gammac down regulation, if any by tumor-secreted PGE2, may fail to support T cells that then become susceptible to apoptotic death [43]. In our experimental model, we observed a marked decrease in the surface expression (Fig. 3A) as well as total amount (Fig. 3B) of IL2Rgamma chain in CD4+ T cells that were co-incubated with tumor supernatants (Fig. 3A). Receptor expression in CD4+ T cells could be efficiently restored back to normal level by theaflavin-treatment of tumor cells (Fig. 3A and 3B).
###end p 25
###begin title 26
###xml 9 10 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 54 55 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor-PGE2 perturbs IL2Rgammac signaling events in CD4+ T cells.
###end title 26
###begin p 27
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 482 483 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 643 644 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 9 14 <span type="species:ncbi:9606">human</span>
Purified human CD4+ T cells, cultured in the presence of media alone or cell-free MCF-7-spent media (+/-theaflavins), were (A) subjected to flow cytometric analysis to determine the surface levels of IL2Rgammac, or lysed for Western blotting of (B) IL2Rgammac, (C) tyrosine phosphorylated Jak-1/Jak-3 and (D) tyrosine phosphorylated Stat-1/Stat-2/Stat-3/Stat-4/Stat-5/Stat-6 using specific antibodies. (E) Jak-3/Stat-5 complexes were immunopurified with anti-Jak-3 antibody from CD4+ T cell lysates. The immunopurified proteins were subjected to Western blot analysis to confirm association of Jak-3 with Stat-5. (F) Nuclear fractions from CD4+ T cells were Western blotted using anti-phospho-Stat-5 antibody to determine nuclear translocation of Stat-5. alpha-Actin and Histone H1 were used as internal loading controls for cytosol and nuclear fractions, respectively.
###end p 27
###begin p 28
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Taniguchi1">[44]</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Oakes1">[45]</xref>
###xml 347 351 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Witthuhn1">[46]</xref>
###xml 436 440 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Zhang1">[47]</xref>
###xml 573 574 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 584 593 580 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3B&#8211;C</xref>
###xml 612 613 608 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 615 622 611 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2A</xref>
###xml 706 715 702 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3B&#8211;C</xref>
###xml 932 941 928 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Figure 3D</xref>
###xml 1041 1042 1037 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1152 1153 1148 1149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1207 1214 1203 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3E</xref>
###xml 1317 1318 1313 1314 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1372 1379 1368 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3E</xref>
###xml 1405 1406 1401 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1684 1693 1672 1681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g003">Fig. 3B&#8211;E</xref>
###xml 1715 1716 1703 1704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1830 1837 1818 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2B</xref>
It has been shown that Jak-3 is required to activate IL2R pathway for T cell proliferation [44] and loss of Jak-3 expression or kinase activity results in impaired activation of the IL2R signaling pathway [45]. Moreover, it is acknowledged that IL2Rgammac is the primary mediator of cytokine signaling and activates Jak-3/Stat-5 signaling cascade [46] by Jak/Stat phosphorylation and subsequent translocation of phospho-Stat to nucleus [47]. We observed that, of the Jak proteins and associated Stat proteins, phosphorylations of Jak-3 and Stat-5 were down regulated in CD4+ T cells (Fig. 3B-C) by tumor-shed PGE2 (Fig. 2A), which could be ameliorated by pre-treatment of the tumor cells with theaflavins (Fig. 3B-C). To test whether Stat-5 was phosphorylated by Jak-3, we co-immunoprecipitated Stat-5 with anti-Jak-3 antibody, and the immunopurified proteins were then Western-blotted with anti-phospho-Stat-5 antibody. Results of Figure 3D showed that tumor supernatant substantially reduced association of phospho-Stat-5 with Jak-3 in CD4+ T cells. Perturbation in phospho-Stat-5 nuclear translocation activity was also observed in tumor-exposed CD4+ T cells in comparison to its untreated counterparts (Fig. 3E). Perturbation in phospho-Stat-5 nuclear translocation activity was also observed in tumor-exposed CD4+ T cells in comparison to its untreated counterparts (Fig. 3E). Interestingly, when CD4+ cells were cultured in presence of theaflavin-pretreated tumor cell supernatants, significant protection towards IL2Rgammac/Jak-3/Stat-5 signaling i.e., up-regulation of gammac expression, Jak-3/Stat-5 association and phosphorylation as well as nuclear localization of Stat-5 (Fig. 3B-E), was observed in CD4+ T cells, which offered them relive from the apoptotic insult that was observed with untreated tumor supernatant (Fig. 2B).
###end p 28
###begin title 29
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Stat-5A transfection confers resistance to CD4+ T cells from tumor-induced death
###end title 29
###begin p 30
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 291 300 291 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Figure-4A</xref>
###xml 316 317 316 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 358 365 358 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g002">Fig. 2A</xref>
###xml 423 430 423 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Fig. 4A</xref>
###xml 432 442 432 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 469 476 469 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Fig. 4A</xref>
###xml 478 489 478 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</italic>
###xml 644 645 644 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 655 662 655 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Fig. 4A</xref>
###xml 664 674 664 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
After confirming the Stat-5-mediated pathway as the major pathway in tumor-induced CD4+ T cell apoptosis, we undertook two different approaches to identify the isoform(s) of Stat-5 involved since both Stat-5A and Stat-5B isoforms play critical role in Bcl-2 induction in T cells. Results of Figure-4A depict that PGE2 present in cell-free tumor supernatant (Fig. 2A) significantly inhibited the phosphorylation of Stat-5A (Fig. 4A, left panel) but not that of Stat-5B (Fig. 4A, right panel). In this situation too, prior treatment of the tumor cells with theaflavins could bring back the phosphorylation status of Stat-5A to normal level in CD4+ T cells (Fig. 4A, left panel).
###end p 30
###begin title 31
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Stat-5A transfection confers resistance to CD4+ T cells from tumor-induced death.
###end title 31
###begin p 32
###xml 12 22 12 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">left panel</italic>
###xml 37 48 37 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">right panel</italic>
###xml 338 353 338 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A/Stat-5B</italic>
###xml 376 383 376 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A</italic>
###xml 383 386 383 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">713</sub>
###xml 387 394 387 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5B</italic>
###xml 394 397 394 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">718</sub>
###xml 423 433 423 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A1*6</italic>
###xml 569 570 567 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 575 576 573 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
A, Stat-5A (left panel) and Stat-5B (right panel) isoforms were immunoprecipitated from cell lysates using specific antibodies and then Western blotted with anti-phospho-tyrosine or anti-Stat-5A/Stat-5B antibodies to determine phosphorylation status of specific proteins. B, Jurkat T cells were transfected with control vector, wild-type Stat-5A/Stat-5B, C-terminal truncated Stat-5A713/Stat-5B718 or constitutively active Stat-5A1*6 genes and were cultured in the presence of media alone or MCF-7 spent media (+/-theaflavins) for 48 h. Percent cell death (Annexin-V-PE+/7AAD+) was determined flow cytometrically. Values are mean+/-S.E.M. of three independent sets of experiments.
###end p 32
###begin p 33
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5</italic>
###xml 209 212 209 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">713</sub>
###xml 202 212 202 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A<sub>713</sub></italic>
###xml 224 227 224 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">718</sub>
###xml 217 227 217 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5B<sub>718</sub></italic>
###xml 254 261 254 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A</italic>
###xml 263 273 263 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A1*6</italic>
###xml 282 289 282 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Fig. 4B</xref>
###xml 428 438 428 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A1*6</italic>
###xml 651 658 651 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Fig. 4B</xref>
###xml 710 713 710 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">713</sub>
###xml 703 713 703 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A<sub>713</sub></italic>
###xml 948 951 948 951 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">718</sub>
###xml 941 951 941 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5B<sub>718</sub></italic>
###xml 1005 1012 1005 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Fig. 4B</xref>
###xml 1030 1037 1030 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat-5A</italic>
###xml 1170 1177 1170 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g004">Fig. 4B</xref>
###xml 1257 1258 1257 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To further confirm the role of two Stat-5 isotypes in tumor-induced CD4+ T cell demise, Jurkat T cells were over-expressed with wild-type Stat-5A/Stat-5B, C-terminal truncated dominant negative Stat-5 (Stat-5A713 and Stat-5B718) or constitutively active Stat-5A (Stat-5A1*6) genes (Fig. 4B) and then incubated with tumor-culture supernatants. Multiple experiments demonstrated that unlike wild-type cells, constitutively active Stat-5A1*6-transfected cells were only minimally affected, with an average of only 6-10% of the transfected cells succumbing to a tumor-supernatant-induced apoptotic death and theaflavins were able to protect them further (Fig. 4B). On the other hand, when dominant negative Stat-5A713 was introduced into Jurkat T cells, this protein rendered these cells more susceptible to tumor-induced death that could not be successfully prevented by theaflavin-administration. In contrast, theaflavins were able to protect Stat-5B718-transfected Jurkat T cells from tumor-induced death (Fig. 4B). When wild-type Stat-5A was introduced into these cells, it was able give protection from tumor-induced death, by itself or in the presence of theaflavins (Fig. 4B). All these results strongly reconfirm our hypothesis that Stat-5A protects CD4+ T cells from tumor-induced apoptosis and theaflavins utilize this isoform of Stat-5 to assert its protective effect.
###end p 33
###begin title 34
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor-shed PGE2 indulges a shift from pro-survival to pro-apoptotic environment in CD4+ T
###end title 34
###begin p 35
###xml 139 143 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Nakajima1">[43]</xref>
###xml 253 254 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 369 370 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 541 542 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 563 572 555 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g005">Figure-5A</xref>
###xml 940 947 932 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g005">Fig. 5A</xref>
###xml 1055 1059 1047 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Li1">[48]</xref>
It is acknowledged that the regulation of both pro- and anti-apoptotic Bcl-2 family proteins is dependent upon the IL2Rgamma chain signals [43] involving Jak-3/Stat-5 cascade. Thus, gammac down regulation and inhibition of Jak-3/Stat-5A signaling by PGE2 present in the tumor supernatant, as obtained here, may fail to support sustained Bcl-2 expression, leading to CD4+ T cells susceptibility towards apoptotic death. To verify this hypothesis, we examined the expression levels of anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins in CD4+ T cells. Results of Figure-5A depict that tumor insult down-regulated Bcl-2 and up-regulated Bax thereby lowering the Bcl-2:Bax ratio and creating a pro-apoptotic environment in these helper cells. Moreover, the expression of Xiap (X-linked inhibitor of apoptosis protein), a member of the inhibitor of apoptosis family of proteins, was diminished in these T cells treated with tumor supernatant (Fig. 5A), making them more susceptible to execution by caspases, as Xiap is known to inhibit caspases-3, -7 and -9 [48].
###end p 35
###begin title 36
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor-shed PGE2 indulges a shift from pro-survival to pro-apoptotic environment in CD4+ T cells.
###end title 36
###begin p 37
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 402 407 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bcl-2</italic>
###xml 411 415 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xiap</italic>
A, Purified CD4+ T cells were cultured in the presence of media alone or MCF-7 spent media (+/-theaflavins) and cell lysates (for the determination of Bcl-2 and Bax) as well as cytosolic fractions (for cytochrome c release, Xiap expression and caspase-3 cleavage) were Western blotted using specific antibodies. alpha-Actin was used as internal loading control. B, Jurkat T cells, wild type as well as Bcl-2 or Xiap transfected, were incubated with media alone or MCF-7-spent media for 48 h. Percent cell death was determined flow cytometrically. Values are mean+/-S.E.M. of four independent sets of experiments in each case.
###end p 37
###begin p 38
###xml 438 445 438 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g005">Fig. 5B</xref>
###xml 677 684 677 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g005">Fig. 5B</xref>
To validate these results, Jurkat T cells were ectopically transfected with Bcl-2 construct. Multiple experiments demonstrated that although control T cells were highly sensitive to tumor supernatant, with an average of 42% of Jurkat cells testing positive for apoptosis, Bcl-2-transfected cells were only minimally affected, with an average of only 12% of the transfected cells succumbing to a tumor supernatant-induced apoptotic death (Fig. 5B). These results led us to ask the question whether over-expression of Xiap would also make these cells more resistant to tumor-induced death. In fact, when these cells were over-expressed with Xiap gene, less killing was observed (Fig. 5B).
###end p 38
###begin p 39
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Hengartner1">[49]</xref>
###xml 253 262 253 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g005">Figure-5A</xref>
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 480 487 480 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g005">Fig. 5A</xref>
###xml 592 593 592 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 684 685 680 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 715 717 711 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2.</sub>
###xml 835 842 831 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g005">Fig. 5A</xref>
###xml 866 867 862 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
It is appreciated that the increase in Bax may cause mitochondrial trans-membrane potential loss that results in the release of cytochrome c in CD4+ T cell cytosol leading to activation of caspase cascades and apoptosis [49]. The experiment depicted in Figure-5A clearly illustrates that culturing CD4+ T cells with MCF-7 cell free supernatant, a significant increase in cytochrome c level in cytosol was observed while in unexposed CD4+ T cell cytosol it was minimally detected (Fig. 5A). Infact, in the downstream, substantial activation of caspase-3 was observed in supernatant-treated CD4+ T cells. These results indicate a total impairment in IL2Rgammac survival signaling in CD4+ T cells by tumor-secreted PGE2. All these factors were restored back to their original levels up on prior treatment of tumor cells with theaflavins (Fig. 5A) thereby protecting CD4+ cells from tumor-induced apoptosis.
###end p 39
###begin title 40
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Re-confirmation of PGE2 as the molecule behind tumor-induced perturbation in CD4+ T cell survival signaling
###end title 40
###begin p 41
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 376 387 376 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 367 387 367 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g006">Fig. 6A, <italic>upper panel</italic></xref>
###xml 404 405 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 437 444 437 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g006">Fig. 6A</xref>
###xml 446 457 446 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 521 522 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 631 638 623 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g006">Fig. 6B</xref>
###xml 640 651 632 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 716 723 708 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g006">Fig. 6B</xref>
###xml 725 736 717 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 824 825 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 851 852 843 844 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 899 906 887 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g006">Fig. 6B</xref>
###xml 908 919 896 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 944 951 932 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007382-g006">Fig. 6B</xref>
###xml 953 964 941 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 1048 1049 1036 1037 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1100 1101 1084 1085 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1296 1297 1280 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Finally, to re-confirm the role of tumor-shed PGE2 in materialising the CD4+ T cell killing effect of tumor, we undertook two approaches. In the first approach, when CD4+ T cells were cultured in presence of supernatants of tumor cells pre-treated with celecoxib or tranfected with Cox-2-siRNA. These treatments caused marked inhibition not only in Cox-2 expression (Fig. 6A, upper panel) but also in PGE2 production by the tumor cells (Fig. 6A, lower panel) and significant protection for the IL2Rgammac signaling in CD4+ T cells i.e., up-regulation of gammac expression, Jak-3/Stat-5 phosphorylation and increase in Bcl-2 level (Fig. 6B, upper panel), which offered these T cells relive from the apoptotic insult (Fig. 6B, lower panel). These findings were again validated in the second approach, in which treatment of CD4+ T cells with purified PGE2 down-regulated IL2Rgammac survival signaling (Fig. 6B, upper panel) and induced apoptosis (Fig. 6B, lower panel). Results from these two approaches well confirmed the importance of tumor-shed PGE2 in impairment of IL2Rgammac survival signal in CD4+ T cells that culminated to apoptosis. Above data also signify that normalization of this signaling pathway may be the mechanism by which theaflavins prevent tumor-induced caspase-3-dependent CD4+ T cell apoptosis.
###end p 41
###begin title 42
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Re-confirmation of PGE2 as the molecule behind tumor-induced perturbation in CD4+ T cell survival signaling.
###end title 42
###begin p 43
###xml 175 186 175 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 310 322 306 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">middle panel</italic>
###xml 381 382 377 378 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 437 448 433 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 466 467 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 617 618 609 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 871 882 851 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 962 973 942 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
A, MCF-7 cells were treated with theaflavins or celecoxib or transfected with Cox-2-siRNA and the levels of Cox-2 and GAPDH (internal control) mRNA were determined by RT-PCR (upper panel). Western blot analysis was performed for the determination of levels of Cox-2 or alpha-Actin (internal control) proteins (middle panel). In parallel experiments the amount of tumor-secreted PGE2 in the cell-free supernatant was determined by ELISA (lower panel). B, Purified CD4+ T cells were cultured in the presence of media alone or MCF-7-spent media (tumors were either pre-treated with 25 microg/ml theaflavins/3.5 ng/ml PGE2/50 microM celecoxib or transfected with 300pmole Cox-2-siRNA) for 48 h. Expression levels of IL2Rgammac and Bcl-2 as well as phosphorylation status of Jak-3/-Stat-5 were determined by Western blotting in which alpha-Actin was used as internal control (upper panel). In parallel experiments, flowcytometric determination of percent cell death (lower panel) was established. Values are mean+/-S.E.M. of three independent experiments.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 193 200 193 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 493 497 493 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Micallef1">[50]</xref>
###xml 909 913 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Das1">[14]</xref>
###xml 915 919 915 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bhattacharyya3">[27]</xref>
###xml 1055 1062 1055 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1067 1075 1067 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1075 1079 1075 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Reichert1">[51]</xref>
###xml 1080 1084 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Rabinowich1">[53]</xref>
###xml 1236 1240 1236 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Saito1">[54]</xref>
###xml 949 954 <span type="species:ncbi:9606">human</span>
A functional immune system is a potential barrier to tumor development and progression. To evade immune mechanisms, many tumors release immunosuppressive factors that attain high concentration in situ and inhibit cell-mediated effector function. Suppression of immune responses, coupled with superior growth kinetics of tumor cells, enable the neoplasm to surpass the control capacity of the host, leading to progressive decreases in cell-mediated anti-tumor responses and accelerated disease [50]. Although the immune system possesses the means to respond to cancer, it often fails to control the spread of malignancy. The fact that numerous laboratories, including our own, find that T lymphocytes undergo the physiological changes associated with apoptosis following co-culture with various cancer cell lines, lends support to the notion that it is the cancer cells themselves that induce lymphocyte death [14], [27]. Recent studies suggest that human carcinoma cells of various origins can activate apoptosis in lymphocytes interacting with the tumor in vivo and in vitro[51]-[53]. This tumor-induced apoptosis of lymphocytes may have important implications for the success of therapeutic regimens, including vaccination strategies [54].
###end p 45
###begin p 46
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kennedy1">[10]</xref>
###xml 323 324 323 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 408 409 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Watanabe1">[55]</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Schoenberger1">[57]</xref>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 593 597 593 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Smith1">[58]</xref>
###xml 639 640 639 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 743 744 743 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 757 761 757 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bevan1">[59]</xref>
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Wang1">[60]</xref>
###xml 827 828 827 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 915 919 915 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kennedy1">[10]</xref>
Ample evidence suggests that CD4+ T cells facilitate the activation and development of anti-tumor responses of CD8+ T cells by enhancing clonal expansion at the tumor site, preventing activation-induced cell death and functioning as antigen-presenting cells for CTLs to preferentially generate immune memory cells [10]. CD4+ T cells assist CD8+ T cell priming via the engagement of CD40-ligand (CD154) on CD4+ T cells and CD40 expressed on DC [55]-[57]. This interaction results in the activation and maturation of DC, making them competent to stimulate antigen-specific CD8+ T cell responses [58]. It is important to note that primary CD8+ T cell responses to nonmicrobial antigens, as in case of cancer, display an absolute dependence on CD4+ T cell help [59], [60]. In this regard, our understanding of the importance of CD4+ T cells in orchestrating immune responses has grown dramatically over the past decade [10]. Here we aimed at elucidating the mechanisms of the tumor-induced suppression of such 'T-cell help' and its amelioration by theaflavins.
###end p 46
###begin p 47
###xml 457 464 <span type="species:ncbi:9606">patient</span>
It has been demonstrated that several carcinoma cell lines produce soluble factors that inhibit T cell proliferation. Because tumor-induced apoptosis of lymphocytes may be mediated by an array of death receptors co-expressed on T cells or by tumor-derived soluble factors, it is important to characterize those intracellular events that may be potential targets for therapeutic intervention to minimize T cell apoptosis since if the immune system of cancer patient is persistently compromised, the success of any kind of therapy would be limited unless the immune system can be appropriately stimulated.
###end p 47
###begin p 48
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Sharma1">[61]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Pockaj2">[62]</xref>
###xml 139 140 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 303 306 303 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Passwell1">[4]</xref>
###xml 308 311 308 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Cayeux1">[5]</xref>
###xml 371 372 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 372 375 372 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kolenko2">[63]</xref>
###xml 517 518 517 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 545 546 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Goodwin1">[64]</xref>
###xml 629 630 629 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 822 823 822 823 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 838 839 838 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 895 896 895 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1020 1024 1020 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Astoul1">[65]</xref>
###xml 1082 1083 1082 1083 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1152 1153 1152 1153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1214 1215 1214 1215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1275 1276 1275 1276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1392 1393 1392 1393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1571 1572 1563 1564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1598 1599 1590 1591 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1802 1803 1786 1787 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1873 1874 1857 1858 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 417 424 <span type="species:ncbi:9606">patient</span>
###xml 886 891 <span type="species:ncbi:9606">human</span>
PGE2 has been implicated as a potential inhibitor of T cell function in the context of malignant disease [61], [62]. Elevated levels of PGE2 have also been found in patients with Hodgkin's lymphoma, which is suggested to be partially responsible for decreased cellular immune function in these patients [4], [5]. Another report confirmed that tumor over-expression of PGE2via the elaboration of Cox-2 directly blocks patient's defence mechanism against cancer and promote cancer growth [63]. It is well known that PGE2 has diverse effects on CD4+ T cells leading to inhibition of T cell activation [64]. Albeit the outcome of PGE2-signaling is well established, the molecular mechanisms involved are still not completely understood. The present study was designed to determine the potential mechanisms of tumor-derived PGE2 leading to CD4+ T cell apoptosis. We exclusively used primary human CD4+ T cells to achieve more physiologic conditions compared with cell line models defective in key enzymes of T cell signaling [65]. Our study demonstrated the presence of Cox-2 derived PGE2 in tumor supernatant and that the effect of tumor supernatant on CD4+ T cells bore remarkable similarities with the effects of PGE2 exposure on these cells. Analysis of data revealed that PGE2 present in cell free tumor supernatant interferes with one of the major pathways for survival and activation of CD4+ T cells. This interference affected gammac expression, Jak-3/Stat-5 phosphorylation and Bcl-2 level suggesting an inhibition of early IL2Rgammac-mediated signaling events in CD4+ cells. We showed that PGE2 leads to down-regulation of IL2Rgammac expression and Jak-3 phosphorylation thereby inactivating the most proximal events of IL2Rgammac signaling. Inability of externally added IL2 to overcome tumor-PGE2 effect indicated that IL2 deprivation is not the primary cause of CD4+ cell death in our system.
###end p 48
###begin p 49
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 337 343 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 343 347 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Kolenko1">[26]</xref>
###xml 416 417 412 413 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 494 497 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 655 659 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Baird1">[66]</xref>
###xml 661 665 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Thomis1">[67]</xref>
###xml 868 869 864 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 888 889 884 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 990 991 986 987 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
Alternatively, theaflavins, which inhibited Cox-2 expression and subsequent PGE2 production in tumor cells, efficiently ameliorated tumor-induced impairment of IL2Rgammac signaling. Recovery of Jak/Stat signaling also altered Bcl-2:Bax ratio in these helper cells in favour of survival. These results are in contrary to those of Kolenko et al.[26] who showed that in renal cancer, impairment in IL2R signaling by PGE2 did not affect IL2-dependent induction of Bcl-2. However, studies with Jak-3-/- knockout mice showing impaired T cell development and severe down-regulation of Bcl-2 protein in T cell populations with moderate increase in Bax expression [66], [67] strengthened our findings. Interestingly, theaflavins offered better protection to T helper cells from tumor-induced death in comparison to either celecoxib or Cox-2-siRNA suggesting that along with PGE2, tumor-induced CD4+ T cell death might have other mediators that are independent of Cox-2 and inhibition of not only PGE2 but also those mediators by theaflavins could be the cause behind observed immunoprotection provided by these polyphenols.
###end p 49
###begin p 50
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 128 129 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 563 564 555 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 595 596 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 766 767 758 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 895 896 887 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 919 920 911 912 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1040 1041 1032 1033 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1115 1116 1107 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1347 1348 1335 1336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1371 1372 1359 1360 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
In conclusion, our data provide direct evidence that tumor-derived Cox-2-dependent PGE2 affects IL2Rgammac-driven signals in CD4+ T cells by down-regulating IL2Rgammac and inactivating Jak resulting in impaired activation of downstream signals as shown by decreased phosphorylation of Stat. As a consequence, Stat phosphorylation and translocation to nucleus as well as anti-apoptotic Bcl-2 and Xiap protein expressions were decreased while increasing Bax thereby activating mitochondrial death cascade in these cells. The functional consequence is a state of CD4+ T cell depletion. Although CD4+ T cells are central to the function of the immune system, their role in tumor immunity remains under-appreciated. Recent advances in understanding of contribution of CD4+ in anti-tumor immunity, as well as some intriguing developments in the clinic, indicate that due to the cooperative role of CD4+ helper T cells for CD8+ cytotoxic T cells, they have the unrealized potential in tumor eradication. Based on our observations, we postulate PGE2 as an important factor responsible for impaired survival signaling in CD4+ T cells thereby leading them towards apoptosis in tumors associated with higher PGE2 production. In addition, our results demonstrating theaflavin-induced protection of IL2Rgammac/Jak-3/Stat-5A signaling as well as survival of CD4+ T cells from tumor PGE2-insult signify that these plant polyphenols may have the potency to sustain the cell mediated immunity of the cancer-bearer that can be utilized for developing an effective therapy of this deadly disease.
###end p 50
###begin title 51
Materials and Methods
###end title 51
###begin title 52
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Isolation of CD4+ T cells
###end title 52
###begin p 53
###xml 518 519 518 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Anastassiou2">[68]</xref>
###xml 683 684 683 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 761 762 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1091 1092 1073 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1487 1488 1469 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 878 884 <span type="species:ncbi:9913">bovine</span>
###xml 1223 1228 <span type="species:ncbi:9606">human</span>
Human venous blood from healthy adult volunteers was collected with informed consent using heparinized syringes. Whole blood (100 mL) was diluted with 150 mL of RPMI 1640 (Sigma, St Louis, MO, USA) and then layered in centrifuge tubes onto 120 mL of Histopaque-1077 (Sigma) gradient. After centrifugation the opaque interface containing lymphocytes was collected, washed twice in RPMI 1640 and, after complete supernatant removal, the pellet was re-suspended in PBS supplemented with 0.5% of BSA and 2 mmol/L EDTA. CD4+ T cells were purified from total leukocytes by positive selection using anti-CD4 antibody coated micro-beads (Milteny Biotech) [68]. The purity of the isolated CD4+ T cells was determined by flow cytometry and was routinely >99% CD3+ and CD4+, but was negative for CD8. Cells were cultured in RPMI 1640 (supplemented with 10 U/ml recombinant IL-2, 10% fetal bovine serum, 2 mM L-glutamine, 100 microg/ml sodium pyruvate, 100 microM non-essential amino acids, 100 microg/ml streptomycin and 50 U/ml penicillin; Sigma) at 37degreesC in humidified incubator containing 5% CO2. Viable cell numbers were determined by Trypan blue exclusion test. The Jurkat T cell line (maintained in complete RPMI 1640) and human mammary epithelial carcinoma cells (MCF-7, MDA-MB-231 and ZR-75-1; maintained in complete DMEM) were obtained from NCCS, India. Tumor supernatants freed from cellular components were used in 1:1 ratio with RPMI to study the effect of tumor supernatant on CD4+ T cells.
###end p 53
###begin p 54
###xml 355 356 351 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 408 409 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 416 417 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 579 580 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 637 638 629 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Tumor cells were pre-treated with different doses of theaflavins (6.25-50 microg/ml), as per the requirement of the experiment, for 90 min after which the culture media containing extra theaflavins were replaced by fresh media. Seventy two-hour old cell-free tumor supernatants were used in 1:1 ratio with RPMI for 48 h to study the effect of tumor on CD4+ T/Jurkat cells. To study the role of tumor-shed PGE2 on CD4+ T apoptosis, supernatants of Cox-2 inhibitor-treated (celecoxib; 50 microM) or Cox-2-siRNA-transfected tumor cells were used. In parallel sets of experiments CD4+ T cells were incubated with 3.5 ng/ml of prostaglandin E2 (Sigma).
###end p 54
###begin title 55
Plasmid constructs, siRNA and transfections
###end title 55
###begin p 56
###xml 125 128 125 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">713</sub>
###xml 167 170 167 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">718</sub>
###xml 211 219 <span type="species:ncbi:9606">Children</span>
Flag-tagged (N-terminus) cDNA encoding full length Stat-5A and Stat-5B, C-terminal truncated Stat-5A (amino acid 713; Stat-5A713) and Stat-5B (amino acids 718; Stat-5B718) (provided by Dr. J.N. Ihle of St. Jude Children's Research Hospital, TN), constitutively active mutant Stat-5A1*6 (generous gift from Prof. T. Kitamura, Institute of Medical Science, University of Tokyo, Japan), Bcl-2, Xiap in Prk5 vector (2 microg/million cells) were introduced separately into Jurkat T cell using T cell nucleofector kit (Amaxa, Koein, Germany). Isolation of stably expressing clones were done by limiting dilution and selection with IL2 (25 U/ml) and hygromycin B (800 mg/ml) for 14 days and cells surviving this treatment were cloned and assessed for Bcl-2 and Stat-5 expressions by Western blot analysis. Tumor cells were transfected with 300pmole of Cox-2-/control-ds-siRNA (Santa Cruz) and lipofectamine 2000 separately for 12 h. Levels of Cox-2 mRNA and protein were estimated by RT-PCR and Western blotting. Transfected cells were cultured for 72 h and cell free supernatants were collected for subsequent experiments.
###end p 56
###begin title 57
Flow cytometry
###end title 57
###begin p 58
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 470 471 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 477 478 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 482 483 482 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 585 586 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
For the determination of cell death, CD4+ T cells were labelled with 7-aminoactinomycin D (7-AAD) and Annexin-V-phycoerythrin (PE) (BD Bioscience) and analyzed on flow cytometer (FACS Calibur; Becton Dickinson), equipped with 488 nm Argon laser light source using CellQuest software. Electronic compensation of the instrument was done to exclude overlapping of the emission spectra. Total 10,000 events were acquired and cells were properly gated for analysis. Annexin-V+/7-AAD+/CD4+ cells were regarded as apoptotic cells. To determine the surface levels of IL2Rgammac expression, CD4+ T cells were incubated with anti-IL2Rgammac (2 microg/ml; Santa Cruz) antibody and then with FITC-conjugated 2nd antibody followed by flowcytometric analysis.
###end p 58
###begin title 59
Co-immunoprecipitation and immunoblotting
###end title 59
###begin p 60
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 344 345 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 489 490 489 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Bhattacharyya4">[69]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007382-Choudhuri1">[70]</xref>
###xml 8 13 <span type="species:ncbi:9606">human</span>
Primary human CD4+ T cells were lysed in buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT) and nuclei were pelleted by brief-centrifugation. The supernatant was spun at 105,000xg to get cytosolic fraction. The nuclear extract was prepared in buffer containing 20 mM HEPES, pH 7.9, 25% (v/v) glycerol, 420 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM PMSF. For whole cell lysate, cells were homogenized in buffer (20 mM Hepes, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM Na-EDTA and 1 mM DTT). All the buffers were supplemented with protease and phosphatase inhibitor cocktails [69], [70]. For direct Western blot analysis, cell lysates or the particular fractions containing 50 microg protein was separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. The protein of interest was visualized by chemiluminescence.
###end p 60
###begin p 61
For the determination of direct interaction between two proteins, co-immunoprecipitation technique was employed. The immunopurified proteins were then detected by Western blot using specific antibody (Santa Cruz). Equal protein loading was confirmed by re-probing the blots with alpha-actin/histone H1 antibody (Santa Cruz).
###end p 61
###begin title 62
###xml 15 16 15 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Prostaglandin E2 assay
###end title 62
###begin p 63
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
PGE2 content in culture supernatants was determined using PGE2 ELIZA bioassay kit (US Biologicals) following the manufacturer's protocol.
###end p 63
###begin title 64
Statistical Analysis
###end title 64
###begin p 65
Values are shown as standard error of mean (SEM) except otherwise indicated. Comparison of multiple experimental groups was performed by 2-way ANOVA followed by a post-hoc Bonferroni multiple comparison test. Data were analyzed and, when appropriate, significance of the differences between mean values was determined by a Student's t test. Results were considered significant at p<0.05.
###end p 65
###begin p 66
###xml 107 110 107 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">713</sub>
###xml 122 125 122 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">718</sub>
###xml 45 53 <span type="species:ncbi:9606">Children</span>
We are grateful to Dr. J.N. Ihle of St. Jude Children's Research Hospital, TN for Stat-5A, Stat-5B, Stat-5A713 and Stat-5B718 clones, and Prof. T. Kitamura, Institute of Medical Science, University of Tokyo, Japan for Stat-5A1*6. We thank Mr. U. Ghosh and Mr. R. Dutta for technical help.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
A new view of prostaglandin E regulation of the immune response.
###end article-title 68
###begin article-title 69
###xml 87 92 <span type="species:ncbi:9606">human</span>
Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases.
###end article-title 69
###begin article-title 70
Prostaglandins as modulators of immunity.
###end article-title 70
###begin article-title 71
Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity.
###end article-title 71
###begin article-title 72
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation.
###end article-title 72
###begin article-title 73
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.
###end article-title 73
###begin article-title 74
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+ T cells and their role in antitumor immune responses.
###end article-title 74
###begin article-title 75
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The role of CD4+ T cell responses in antitumor immunity.
###end article-title 75
###begin article-title 76
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors.
###end article-title 76
###begin article-title 77
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Multiple roles for CD4+ T cells in anti-tumor immune responses.
###end article-title 77
###begin article-title 78
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.
###end article-title 78
###begin article-title 79
Help for cytotoxic-T-cell responses is mediated by CD40 signalling.
###end article-title 79
###begin article-title 80
T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
###end article-title 80
###begin article-title 81
Tumors Induce T Cell Apoptosis Through Receptor-Dependent and Receptor-Independent Pathways.
###end article-title 81
###begin article-title 82
GM1 and TNFa, overexpressed in renal cell carcinoma, synergize to induce T cell apoptosis.
###end article-title 82
###begin article-title 83
GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells.
###end article-title 83
###begin article-title 84
Tumor-induced oxidative stress perturbs NFkappaB activity augmenting TNFalpha-mediated T cell death: Protection by curcumin.
###end article-title 84
###begin article-title 85
###xml 0 9 <span type="species:ncbi:4442">Black tea</span>
Black tea-induced decrease in IL-10 and TGF-beta of tumor cells promotes Th1/Tc1 response in tumor-bearer.
###end article-title 85
###begin article-title 86
Where have all the T cells gone? Mechanisms of immune evasion by tumors.
###end article-title 86
###begin article-title 87
Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction.
###end article-title 87
###begin article-title 88
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">via</italic>
Tumor-induced thymic involution via Inhibition of IL-7Ralpha and its JAK-STAT signaling pathway: Protection by Black Tea. Int.
###end article-title 88
###begin article-title 89
###xml 28 29 28 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma.
###end article-title 89
###begin article-title 90
###xml 123 131 <span type="species:ncbi:9606">patients</span>
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.
###end article-title 90
###begin article-title 91
###xml 46 51 <span type="species:ncbi:9606">human</span>
Delineation of the mechanism of inhibition of human T cell activation by PGE2.
###end article-title 91
###begin article-title 92
Duration of CTL activation regulates IL2 production required for autonomous clonal expansion.
###end article-title 92
###begin article-title 93
Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway.
###end article-title 93
###begin article-title 94
Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction.
###end article-title 94
###begin article-title 95
Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL2 and IL2R alpha gene expression at multiple levels.
###end article-title 95
###begin article-title 96
Increased intracellular cyclic AMP inhibits inositol phospholipid hydrolysis induced by perturbation of the T cell receptor/CD3 complex but not by G-protein stimulation. Association with protein kinase A-mediated phosphorylation of phospholipase C-gamma 1.
###end article-title 96
###begin article-title 97
Molecular thanatopsis: a discourse on the BCL2 family and cell death.
###end article-title 97
###begin article-title 98
Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development.
###end article-title 98
###begin article-title 99
Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase.
###end article-title 99
###begin article-title 100
Effects of PGE2 upon differentiation and programmed cell death of suspension cultured CD4-CD8- thymocytes.
###end article-title 100
###begin article-title 101
Induction of apoptosis in thymocytes by prostaglandin E2 in vivo.
###end article-title 101
###begin article-title 102
Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2.
###end article-title 102
###begin article-title 103
Contribution of p53-mediated transcription-dependent pathway in mammary epithelial carcinoma cell apoptosis by theaflavins.
###end article-title 103
###begin article-title 104
###xml 96 101 <span type="species:ncbi:9606">human</span>
Theaflavins induce G2/M arrest by modulating expression of p21waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells.
###end article-title 104
###begin article-title 105
Inhibition of lung tumorigenesis by tea.
###end article-title 105
###begin article-title 106
Characteristics of catechin- and theaflavin-mediated cardioprotection.
###end article-title 106
###begin article-title 107
###xml 17 26 <span type="species:ncbi:4442">black tea</span>
Theaflavins from black tea, especially theaflavin-3-gallate, reduce the incorporation of cholesterol into mixed micelles.
###end article-title 107
###begin article-title 108
###xml 28 37 <span type="species:ncbi:4442">black tea</span>
Antioxidative properties of black tea.
###end article-title 108
###begin article-title 109
Common gamma chain cytokines: dissidence in the details.
###end article-title 109
###begin article-title 110
The common cytokine receptor gamma-chain plays an essential role in regulating lymphoid homeostasis.
###end article-title 110
###begin article-title 111
The IL2/IL2 receptor system: A current overview.
###end article-title 111
###begin article-title 112
Signaling via IL2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways.
###end article-title 112
###begin article-title 113
Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells.
###end article-title 113
###begin article-title 114
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
###end article-title 114
###begin article-title 115
###xml 23 28 <span type="species:ncbi:9606">human</span>
Chemically synthesized human survivin does not inhibit caspase-3.
###end article-title 115
###begin article-title 116
The biochemistry of apoptosis.
###end article-title 116
###begin article-title 117
###xml 29 35 <span type="species:ncbi:10090">murine</span>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites.
###end article-title 117
###begin article-title 118
Mechanisms responsible for signaling and functional defects.
###end article-title 118
###begin article-title 119
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
###end article-title 119
###begin article-title 120
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.
###end article-title 120
###begin article-title 121
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma.
###end article-title 121
###begin article-title 122
The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity.
###end article-title 122
###begin article-title 123
Dendritic cells require T cells for functional maturation in vivo.
###end article-title 123
###begin article-title 124
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.
###end article-title 124
###begin article-title 125
Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity.
###end article-title 125
###begin article-title 126
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Helping the CD8+ T- cell response.
###end article-title 126
###begin article-title 127
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cutting Edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo.
###end article-title 127
###begin article-title 128
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
###end article-title 128
###begin article-title 129
###xml 123 131 <span type="species:ncbi:9606">patients</span>
Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.
###end article-title 129
###begin article-title 130
###xml 159 164 <span type="species:ncbi:9606">human</span>
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL2 receptor signaling: role of soluble products from human renal cell carcinomas.
###end article-title 130
###begin article-title 131
###xml 15 20 <span type="species:ncbi:9606">human</span>
Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell.
###end article-title 131
###begin article-title 132
PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models.
###end article-title 132
###begin article-title 133
###xml 52 56 <span type="species:ncbi:10090">mice</span>
T cell development and activation in Jak3-deficient mice.
###end article-title 133
###begin article-title 134
Peripheral expression of Jak3 is required to maintain T lymphocyte function.
###end article-title 134
###begin article-title 135
Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL2 and IL2R alpha gene expression at multiple levels.
###end article-title 135
###begin article-title 136
###xml 0 9 <span type="species:ncbi:4442">Black tea</span>
Black tea induces tumor cell apoptosis by Bax translocation, loss in mitochondrial transmembrane potential, cytochrome c release and caspase activation.
###end article-title 136
###begin article-title 137
Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner.
###end article-title 137
###begin p 138
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 138
###begin p 139
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by research grants from Department of Science and Technology, Council of Scientific and Industrial Research and Indian Council of Medical Research, Govt. of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 139

